Literature DB >> 12835096

Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

R Maggio1, M Armogida, M Scarselli, F Salvadori, B Longoni, C Pardini, A Chiarenza, S Chiacchio, F Vaglini, R Bernardini, A Colzi, G U Corsini.   

Abstract

Epidemiological studies have shown a reduced incidence of cancer in Parkinson's disease. Since nearly all parkinsonian patients with clinical impairment are treated with L-beta-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine (DA)ergic agonists, a possibility exists that these therapeutic agents can influence the risk of cancer. We studied the antiproliferative effect of these therapeutic agents (and substances structurally correlated) on Chinese hamster ovary (CHO)-K1 cell growth. Among the compounds tested, apomorphine proved to be the most potent inhibitor of CHO-K1 cell growth, with an EC(50) of 3.35 +/- 0.12 micro M. The apomorphine analogues, apocodeine and hydroxyethylnorapomorphine, were less active as inhibitors of CHO-K1 cell growth. The activity of DA, 6-hydroxydopamine (6-OHDA), phenylethylamine (PEA), L-DOPA and bromocriptine as antiproliferative was one order of magnitude lower than that of apomorphine while pergolide was ineffective. To test whether or not the oxidative potential of these compounds was important for their antiproliferative effect, several antioxidants were assayed. Among them glutathione (GSH) and dithiothreitol (DTT) were effective in reversing the anti-proliferative effect of apomorphine, DA, 6-OHDA and PEA, conversely they did not work with bromocriptine. GSH and DTT are sulphydryl-reducing agents; while their effect could explain the efficacy against apomorphine, DA and 6-OHDA, it is difficult to understand why they should have any effect on PEA as this substance does not react with sulphydryl groups. The oxidative potential as a mechanism of action was also questioned by the results obtained with dihydrorhodamine 123, a probe that changes its fluorescent emission wave when oxidized. None of the compounds, with the exception of 6-OHDA, had any effect on the fluorescent emission wave of the probe at the maximal concentrations used to inhibit CHO-K1 cell growth. At concentrations five times higher, apomorphine and DA generated reactive oxygen species but PEA and bromocriptine did not. These data demonstrate that the antiproliferative effect of these compounds is not due to their oxidative potential, but another mechanism must be postulated.

Entities:  

Year:  2000        PMID: 12835096     DOI: 10.1007/bf03033258

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  45 in total

1.  Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.

Authors:  G Cohen
Journal:  Adv Neurol       Date:  1987

2.  Apomorphine inhibits the growth-stimulating effect of retinal pigment epithelium on scleral cells in vitro.

Authors:  Y Seko; Y Tanaka; T Tokoro
Journal:  Cell Biochem Funct       Date:  1997-09       Impact factor: 3.685

3.  Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.

Authors:  U M Schrell; R Fahlbusch; E F Adams; P Nomikos; M Reif
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

4.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

Authors:  B Pardo; M A Mena; M J Casarejos; C L Paíno; J G De Yébenes
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

5.  Gluconeogenesis in rat hepatocytes from monomethyl succinate and other esters.

Authors:  R Rognstad
Journal:  Arch Biochem Biophys       Date:  1984-05-01       Impact factor: 4.013

6.  Apoptosis in the anterior pituitary gland of the rat: studies with estrogen and bromocriptine.

Authors:  N Drewett; J M Jacobi; D A Willgoss; H M Lloyd
Journal:  Neuroendocrinology       Date:  1993-01       Impact factor: 4.914

7.  Toxic and protective effects of L-dopa on mesencephalic cell cultures.

Authors:  C Mytilineou; S K Han; G Cohen
Journal:  J Neurochem       Date:  1993-10       Impact factor: 5.372

8.  Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size.

Authors:  J F Bonneville; D Poulignot; F Cattin; M Couturier; E Mollet; J L Dietemann
Journal:  Radiology       Date:  1982-05       Impact factor: 11.105

9.  Antioxidant properties of bromocriptine, a dopamine agonist.

Authors:  T Yoshikawa; Y Minamiyama; Y Naito; M Kondo
Journal:  J Neurochem       Date:  1994-03       Impact factor: 5.372

10.  Influence of metoclopramide and bromocriptine upon the growth of human and murine neuroblastoma cells.

Authors:  E Busse; O Bartsch; A Schneider; B Kornhuber
Journal:  Oncology       Date:  1990       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.